Pancreatic Cancer Clinical Trials in Tampa, Florida

15 studies are recruiting for pancreatic cancer in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    20 in total
    Run by
    IDEAYA Biosciences

    See if you can join NCT07277413 on ClinicalTrials.gov

  2. Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

    The Florida Pancreas Collaborative wants to partner with individuals who are known to have, or are suspected to have a pancreatic lesion, tumor, cyst, mass, cancer, or pancreatitis and are undergoing diagnosis and treatment at a participating institution. The goals of this project are to build a la…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    3 in total
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT04275557 on ClinicalTrials.gov

  3. Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

    The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).

    Stage
    Not phased
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06423963 on ClinicalTrials.gov

  4. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Locations
    49 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07491445 on ClinicalTrials.gov

  5. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    9 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07621718 on ClinicalTrials.gov

  6. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07805954 on ClinicalTrials.gov

  7. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    16 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

  8. Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

    The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study ai…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    ARTIDIS AG

    See if you can join NCT07542041 on ClinicalTrials.gov

  9. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    2 in total
    Run by
    Memgen, Inc.

    See if you can join NCT05076760 on ClinicalTrials.gov

  10. Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

    This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    2 in total
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05687188 on ClinicalTrials.gov

  11. BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

    BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX c…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    24 in total
    Run by
    Bold Therapeutics, Inc.

    See if you can join NCT04421820 on ClinicalTrials.gov

  12. A First-in-Human Study of FID-022 in Solid Tumor Patients

    This observational study aims to (1) validate a multimodal artificial intelligence (AI) model for early detection of cancer-associated cachexia in pancreatic cancer patients and (2) assess the feasibility and acceptability of diet and exercise interventions for cachexia management. The study will u…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT07249775 on ClinicalTrials.gov

  13. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt, Tampa, Florida
    Locations
    35 in total
    Run by
    Apollomics Inc.

    See if you can join NCT03175224 on ClinicalTrials.gov

  14. Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

    Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Tampa General Hospital, Tampa, Florida
    Locations
    6 in total
    Run by
    CivaTech Oncology

    See if you can join NCT02843945 on ClinicalTrials.gov

  15. American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

    The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of South Florida, Tampa, Florida
    Locations
    16 in total
    Run by
    University of Louisville

    See if you can join NCT02674100 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.